Status:

NOT_YET_RECRUITING

Analysis of Paediatric Treatments With multiFiltratePRO

Lead Sponsor:

Fresenius Medical Care Deutschland GmbH

Collaborating Sponsors:

Alcedis GmbH

Conditions:

Renal Failure

CVVHD

Eligibility:

All Genders

Up to 18 years

Phase:

NA

Brief Summary

This clinical study evaluates the performance of the MultifiltratePro in pediatric mode for Continuous Venovenous Hemodiafiltration (CVVHD) in children. Its primary aim is to assess the efficacy of th...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • General:
  • Paediatric Patients:
  • Informed consent signed and dated by legal representative and investigator/ authorized physician.
  • The minors have received the information referred to in Article 63(2) MDR in a way adapted to their age and mental maturity and from investigators or members of the investigating team who are trained or experienced in working with children.
  • The explicit wish of a minor who is capable of forming an opinion and assessing the information referred to in Article 63(2) MDR to refuse participation in, or to withdraw from, the clinical investigation at any time, is respected by the investigator.
  • Study-specific:
  • Estimated life expectancy greater than 3 days
  • Children under 18 years
  • Body weight ≥8kg and \<40kg
  • Patients with clinical indication for CVVHD
  • Exclusion criteria:
  • General:
  • Any conditions which could interfere with the patient's ability to comply with the study
  • Patient or legal representative is not able to give informed consent according to European Medical Device Regulation and corresponding national regulations
  • In case of female patients: pregnancy or lactation period
  • Participation in an interventional clinical study during the preceding 30 days
  • Previous participation in the same study
  • Study-specific:
  • Hypersensitivity to heparin or known history of heparin induced thrombocytopenia (HIT Type II)
  • Uncontrolled bleeding and coagulation disorders
  • Decision to limit therapeutic interventions
  • Inability to establish the required vascular access

Exclusion

    Key Trial Info

    Start Date :

    October 1 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2026

    Estimated Enrollment :

    43 Patients enrolled

    Trial Details

    Trial ID

    NCT06603324

    Start Date

    October 1 2025

    End Date

    December 1 2026

    Last Update

    September 4 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Universitätsklinikum Frankfurt

    Frankfurt, Germany, 60590